Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
Karen Fancher, Jeremy J. Pappacena
Topics & Concepts
IbrutinibBruton's tyrosine kinaseDrugTyrosine kinasePharmacologyFood and drug administrationMedicineReceptorImmunologyInternal medicineChronic lymphocytic leukemiaLeukemiaChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsPI3K/AKT/mTOR signaling in cancer